ダロルタミド
ダロルタミド 物理性質
- 融点 :
- 169 - 171°C
- 沸点 :
- 719.5±60.0 °C(Predicted)
- 比重(密度) :
- 1.41±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- -20°C Freezer, Under inert atmosphere
- 溶解性:
- DMSO(微量)、メタノール(微量)
- 酸解離定数(Pka):
- 11.10±0.10(Predicted)
- 外見 :
- 個体
- 色:
- ホワイトからオフホワイト
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
ダロルタミド 価格
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
ダロルタミド 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, アンドロゲン受容体拮抗薬
説明
ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies.
使用
ODM-201 is a compound being used as a novel next-generation androgen receptor-directed therapy for prostate cancer.
参考文献
Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007.
Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013.
Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85.
ダロルタミド 上流と下流の製品情報
原材料
準備製品
ダロルタミド 生産企業
Global( 185)Suppliers
1297538-32-9(ダロルタミド)キーワード:
- 1297538-32-9
- ODM-201
- N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
- N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
- Darolutamide (ODM-201)
- ODM-201(BAY-1841788)
- CS-1565
- ODM-201(Darolutamide)
- N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide
- 0DM021
- BAY-1841788;ODM-021;0DM021;ODM 021
- ODM 021
- ODM-021
- DAROLUTAMIDE;BAY-1841788
- 1H-Pyrazole-3-carboxamide, N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-
- Darolutamid
- Darolutamide D4
- N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)Chemicalbook-1-hydroxyethyl]-1H-pyrazole-3-carboxamide
- TIANFUCHEM--1297538-32-9---ODM-201
- BAY-1841788
- Darolutamide
- N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
- N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-(1-hydroxyethyl)-1H-pyrazole-5-carboxamide
- Dantrolene Impurity 6
- Darolutamide, ODM-201,BAY-1841788
- Darrolumide
- ダロルタミド
- ダロルタミド (JAN)
- N-[(S)-1-(3-(3-クロロ-4-シアノフェニル)-1H-ピラゾール-1-イル)プロパン-2-イル]-5-(1-ヒドロキシエチル)-1H-ピラゾール-3-カルボアミド
- N-[(2S)-1-[3-(3-クロロ-4-シアノフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル]-5-(1-ヒドロキシエチル)-1H-ピラゾール-3-カルボキサミド
- N-[(S)-1-[3-(3-クロロ-4-シアノフェニル)-1H-ピラゾール-1-イル]プロパン-2-イル]-5-(1-ヒドロキシエチル)-1H-ピラゾール-3-カルボアミド